Abstract: This invention provides novel cyclic hydrocarbons of the formula: ##STR1## wherein R is selected from the group consisting of CH.sub.2 .dbd.CH--CH.sub.2 --, HO--CH.sub.2 CH.sub.2 CH.sub.2 --, and CH.sub.3 ;wherein R.sub.1 is selected from the group consisting of m-trifluoromethylphenylmethyl, 2-thienylmethyl, and p-aminosulfonylphenylethyl;wherein R.sub.2 and R.sub.3 are methyl or hydrogen;wherein R.sub.4 is hydrogen or --OH;a compound of the formula ##STR2## wherein R is (CH.sub.3).sub.2 NCH.sub.2 CH.sub.2 CH.sub.2 -- or NH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 --;or a compound of the formula ##STR3## wherein the dashed line indicates that the 2-3 bond is saturated or unsaturated and, wherein R is hydrogen or methyl.These compounds are useful for inhibiting adverse physiological symptoms associated with phospholipase A.sub.2 and for treating hyperglycemia associated diseases such as diabetes and obesity.

Abstract: Novel 1,4-naphthalenediol and 1,4-hydroquinone derivatives of formula I, II, III and IV and their therapeutic uses as 5-lipoxygenase inhibitors, leukotriene inhibitors, antiinflammatory and/or inhibitors of mucus secretion agents are described. Also provided are novel intermediates useful for the preparation of said derivatives.

Abstract: Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.

Abstract: Novel 1,4-naphthalenediol and 1,4-hydroquinone derivatives of formulas I, II, III and IV and their therapeutic uses as 5-lipoxygenase inhibitors, leukotriene inhibitors, antiinflammatory and/or inhibitors of mucus secretion agents are described. Also provided are novel intermediates useful for the preparation of said derivatives.

Abstract: The present invention provides novel benzenediols and benzedioxins which selectively inhibit thromboxane A.sub.2 synthetase and as such represent useful and potent pharmacological agents.

Abstract: The present invention provides a process for the preparation of 11.alpha.-alkylprostaglandin E compounds from corresponding prostaglandin A compounds via reaction with alkyllithium complexes, and novel 11-deoxy-11.alpha.-alkylprostaglandin E compounds useful for the same pharmacological purposes as the natural PGE compounds, e.g., antiulcer and antisecretory effects.

Abstract: This invention comprises certain analogs PGE or 11-deoxy-PGE compounds in which the carbonyl at C-9 is replaced by methylene. Also provided in this invention, are novel chemical processes and novel chemical intermediates useful in the preparation of the above prostaglandin analogs. These prostaglandin analogs exhibit prostaglandin-like activity, and are accordingly useful for the same pharmacological purposes as the prostaglandins. Among these purposes are blood pressure lowering, labor induction at term, reproductive-cycle regulation, gastric antisecretory action, and the like.

Abstract: The present invention provides novel imidazolyl-benzofurans and derivatives thereof which are useful as thromboxane A.sub.2 (TXA.sub.2) synthetase inhibitors and as such represent potent pharmacological agents.

Abstract: The present invention provides novel 9-deoxy-9-methylene-6-keto-PGE derivatives which are useful for platelet aggregation inhibition and gastric cyctoprotection.

Abstract: The present specification relates to novel 9-deoxy-9-methylene-trans-2,3-didehydro-PGF compounds with improved pharmacological properties. While these compounds are useful in inducing a wide variety of prostaglandin-like pharmacological effects, they are specifically useful as regulators of procreation and fertility.

Abstract: The present invention provides novel thromboxane analogs and intermediates. Particularly, the present invention provides novel 11a-methano-TXA.sub.2 amides.

Abstract: The present invention particularly relates to novel .omega.-aryl-9-deoxy-9-methylene-5,6-didehydro-PFG.sub.1 compounds and methods for their preparation in pharmacological use.

Abstract: The present invention provides novel isoxazolyl derivatives prepared from 9.alpha.,11.alpha.-epoxyimino-9,11,15-trideoxy-PGF-type compounds. These novel compounds are useful as anti-inflammatory agents, anti-asthma agents, and platelet aggregation inhibitors in mammals and especially in humans.

Abstract: The present invention provides novel thromboxane analogs and intermediates. Particularly, the present invention provides novel 2-decarboxy-2-hydroxymethyl-11a-homo-TXA.sub.2 compounds.

Abstract: The present invention particularly relates to novel 9-deoxy-9-methylene-5,6-didehydro-PGF.sub.1 amides and methods for their preparation in pharmacological use.

Abstract: The present invention provides novel thromboxane analogs and intermediates. Particularly, the present invention provides novel 2-decarboxy-2-aminomethyl-11a-methano-TXA.sub.2 compounds.

Abstract: The present invention particularly relates to novel 2-decarboxy-2-hydroxymethyl-9-deoxy-9-methylene-5,6-didehydro-PGF.sub.1 compounds and methods for their preparation in pharmacological use.

Abstract: The present invention provides novel thromboxane analogs and intermediates. Particularly, the present invention provides novel 11a-homo-PG intermediates for preparing 11a-methano TXA.sub.2 compounds.

Abstract: The present invention particularly relates to novel 2-decarboxy-2-aminomethyl-9-deoxy-9-methylene-5,6-didehydro-PGF.sub.1 compounds and methods for their preparation in pharmacological use.

Abstract: The present invention provides novel 16-phenoxy-9-deoxy-9-methylene-PGF-type compounds, exhibiting pharmacological properties comparable to the corresponding prostaglandin E-type compounds.